NO20090692L - Farmasoytiske og kostholdsprodukter som omfatter vitamin K2 - Google Patents

Farmasoytiske og kostholdsprodukter som omfatter vitamin K2

Info

Publication number
NO20090692L
NO20090692L NO20090692A NO20090692A NO20090692L NO 20090692 L NO20090692 L NO 20090692L NO 20090692 A NO20090692 A NO 20090692A NO 20090692 A NO20090692 A NO 20090692A NO 20090692 L NO20090692 L NO 20090692L
Authority
NO
Norway
Prior art keywords
vitamin
pharmaceutical
oil
compounds
class
Prior art date
Application number
NO20090692A
Other languages
English (en)
Other versions
NO343923B1 (no
Inventor
Jo Klaveness
Hogne Vik
Stein Westbye
Cees Vermeer
Leon J Schurgers
Anne Bjornebye Vik
Original Assignee
Nattopharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38820269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090692(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nattopharma Asa filed Critical Nattopharma Asa
Priority to NO20090692A priority Critical patent/NO343923B1/no
Publication of NO20090692L publication Critical patent/NO20090692L/no
Publication of NO343923B1 publication Critical patent/NO343923B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et farmasøytisk og nutrasøytisk produkt er tilveiebrakt som innbefatter vitamin K2 eller en forbindelse innenfor vitamin K2 klassen av forbindelser, eventuelt og fortrinnsvis i kombinasjon med en eller flere flerumettede fettsyrer, enten i renset form eller som en marin olje (dvs. fiske- og/eller krillolje). Også tilveiebrakt er anvendelsen av vitamin K2 eller en forbindelse innenfor vitamin K2 klassen av forbindelser, fortrinnsvis i kombinasjon med en eller flere flerumettede fettsyrer, enten i renset form eller som en marin olje, ved behandling eller profylakse av forstyrrelser relatert til ben, brusk og det kardiovaskulære systemet. Foretrukne forbindelser innenfor vitamin K2 klassen av forbindelser er MK-7, MK-8, MK-9 og MK-10, særlig MK-7 eller MK-9. Den marine oljen er foretrukket krillolje eller fiskeolje.
NO20090692A 2006-07-14 2009-02-12 Farmasøytiske og nutrasøytiske produkter som innbefatter minst en forbindelse innenfor vitamin K2 klassen og slike produkter for forebygging eller terapi av forstyrrelser relatert til ben, brusk og det kardiovaskulære systemet. NO343923B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20090692A NO343923B1 (no) 2006-07-14 2009-02-12 Farmasøytiske og nutrasøytiske produkter som innbefatter minst en forbindelse innenfor vitamin K2 klassen og slike produkter for forebygging eller terapi av forstyrrelser relatert til ben, brusk og det kardiovaskulære systemet.

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NO20063292 2006-07-14
NO20063291 2006-07-14
NO20063988 2006-09-06
PCT/EP2007/006241 WO2008006607A2 (en) 2006-07-14 2007-07-13 Pharmaceutical and nutraceutical products comprising vitamin k2
NO20090692A NO343923B1 (no) 2006-07-14 2009-02-12 Farmasøytiske og nutrasøytiske produkter som innbefatter minst en forbindelse innenfor vitamin K2 klassen og slike produkter for forebygging eller terapi av forstyrrelser relatert til ben, brusk og det kardiovaskulære systemet.

Publications (2)

Publication Number Publication Date
NO20090692L true NO20090692L (no) 2009-04-01
NO343923B1 NO343923B1 (no) 2019-07-08

Family

ID=38820269

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090692A NO343923B1 (no) 2006-07-14 2009-02-12 Farmasøytiske og nutrasøytiske produkter som innbefatter minst en forbindelse innenfor vitamin K2 klassen og slike produkter for forebygging eller terapi av forstyrrelser relatert til ben, brusk og det kardiovaskulære systemet.

Country Status (10)

Country Link
US (1) US20100048704A1 (no)
EP (1) EP2046312B1 (no)
JP (2) JP5827784B2 (no)
AU (1) AU2007271900B2 (no)
CA (1) CA2657748C (no)
ES (1) ES2790590T3 (no)
NO (1) NO343923B1 (no)
NZ (1) NZ574882A (no)
PL (1) PL2046312T3 (no)
WO (1) WO2008006607A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
NL1034964C2 (nl) * 2008-01-28 2009-07-30 Friesland Brands Bv Werkwijze en composities voor de behandeling van botaandoeningen.
GB0817701D0 (en) * 2008-09-26 2008-11-05 Omegatri As Krill oil powder and krill oil tablets
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
FR2949044B1 (fr) 2009-08-12 2021-05-07 Expanscience Lab Composition comprenant une fraction d'insaponifiable
WO2011031601A2 (en) * 2009-09-14 2011-03-17 Nestec S.A. Nutritional compositions including exogenous vitamin k2
GB2476644B (en) * 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
WO2012019032A1 (en) * 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
WO2012059942A2 (en) * 2010-11-01 2012-05-10 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin mk-7
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
PH12013502396A1 (en) * 2011-05-20 2019-07-17 Friesland Brands Bv Composition comprising vitamin k2
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
EP2886129A1 (en) 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
ES2937960T5 (en) 2015-02-11 2026-02-16 Aker Biomarine Human Ingredients As Lipid extraction processes
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
US11160759B1 (en) 2015-10-09 2021-11-02 Combocap, Inc. Capsule with internal diaphragm for improved bioavailability
BR112020019832A2 (pt) 2018-03-30 2021-01-05 Kaydence Pharma As Métodos para melhorar função cardiovascular, elasticidade, velocidade de onda de pulso ou disfunção endotelial, reduzir rigidez arterial e/ou para reverter calcificação de um vaso sanguíneo em um mamífero e para aumentar produção de óxido nítrico endotelial em um sujeito, e, kit
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
IL279245B2 (en) * 2018-06-08 2024-03-01 Epizon Pharma Inc Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification
WO2021165859A1 (en) * 2020-02-19 2021-08-26 Yogesh Dound A composition comprising vitamin k2-7 in combination with vitamin k-1 in purest form
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
JP2577584B2 (ja) * 1987-11-13 1997-02-05 雪印乳業株式会社 多価不飽和脂肪酸とビタミンａを含有する組成物の保存方法
US5180747A (en) * 1989-02-28 1993-01-19 Nisshin Flour Milling Co., Ltd. Stabilized fat-soluble vitamin compositions
JPH03254658A (ja) * 1990-03-01 1991-11-13 Binshiyoo:Kk 納豆によるスナック食品の製造法
JPH04253908A (ja) * 1990-12-28 1992-09-09 Nippon Oil & Fats Co Ltd 骨粗鬆症治療薬
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
GB9713620D0 (en) 1997-06-28 1997-09-03 Boots Co Plc Composition
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DK1153548T3 (da) 2000-05-12 2007-09-10 Nattopharma Asa Levnedsmiddelprodukt, der indeholder vitamin k2
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
ES2289097T3 (es) * 2001-03-15 2008-02-01 Dsm Ip Assets B.V. Composicion para la prevencion de la osteoporosis consistente de una combinacion de isoflavonas y acidos grasos poliinsaturados.
CN102319266B (zh) * 2001-06-18 2014-12-17 海王星技术&生物资源有限公司 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
ATE334649T1 (de) * 2001-10-09 2006-08-15 Res Foundation Suny Gerät zur behanldung der orthostatischen hypotonie
JP2003169632A (ja) 2001-12-08 2003-06-17 Sapuri:Kk 米胚芽油、卵黄油及びホスファチジルセリン含有の健康食品
JP2003313142A (ja) * 2002-02-20 2003-11-06 En Otsuka Pharmaceutical Co Ltd 栄養組成物
JP3999532B2 (ja) * 2002-02-26 2007-10-31 三菱重工業株式会社 輸送用冷凍装置
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
JP2005237300A (ja) * 2004-02-26 2005-09-08 Aichi Prefecture 食品素材及びその製造方法

Also Published As

Publication number Publication date
WO2008006607A2 (en) 2008-01-17
NZ574882A (en) 2012-08-31
ES2790590T3 (es) 2020-10-28
CA2657748A1 (en) 2008-01-17
AU2007271900B2 (en) 2013-05-23
CA2657748C (en) 2014-10-21
EP2046312B1 (en) 2020-02-19
EP2046312A2 (en) 2009-04-15
JP2014031378A (ja) 2014-02-20
PL2046312T3 (pl) 2021-02-08
WO2008006607A3 (en) 2008-10-23
NO343923B1 (no) 2019-07-08
US20100048704A1 (en) 2010-02-25
JP5827784B2 (ja) 2015-12-02
JP2009544590A (ja) 2009-12-17
AU2007271900A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
MX344588B (es) Produccion de acidos grasos y derivados de los mismos.
EP2840131A3 (en) Production of fatty acids and derivatives thereof
AU2003219077A1 (en) Oxidation of o-xylol to form o-toluic acid and other oxidation products by the staggered supply of an oxygen-containing gas
WO2009099830A3 (en) Edible film-strips for immediate release of active ingredients
WO2008129358A3 (en) Oil producing microbes and methods of modification thereof
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
WO2007117511A3 (en) Feed formulations containing docosahexaenoic acid
WO2005079797A3 (en) Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
WO2009013596A3 (en) Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
WO2012119078A3 (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
BRPI0410859A (pt) concentrado de carotenóide purificado, composição de carotenóide purificada diluìda, composição adequada para administração oral, substáncia alimentìcia ou bebida adequada para consumo de mamìfero, e, creme, loção ou ungüento tópico
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
WO2008119457A3 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
ATE538666T1 (de) Nahrungsergänzung zur verhinderung von abmagerungen
WO2009064023A8 (en) Skin moisturizer, blood circulation promoter, and external preparations for the skin containing the skin moisturizer and the blood circulation promoter
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
DE602004019884D1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
WO2006123031A3 (fr) Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise
WO2007125562A3 (en) Method for the preparation and use of an enriched cyanidine-s-o-beta-glucopyranoside extract and derivatives thereof from fruits and vegetables containing said anthocyanin and method for the purification and use of cyanidine-3-o-beta- glucopyranoside and derivatives thereof obtained

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PHARMACO AS, NO

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NATTOPHARMA AS, NO

CREP Change of representative